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Background: In the course of the outbreak of Rift Valley fever
virus in South Africa between 2010 and 2011, and prior to the out-
break, samples were collected for detection of other arboviruses,
speciﬁcally ﬂaviviruses. Flaviviruses are divided into mosquito-
borne and tick-borne species. The presence of mosquito-borne
ﬂavivirus species West Nile virus (WNV) and Wesselsbron virus
(WESSV) in southern Africa is well established; however their
prevalence remains unknown. This is largely due to the high sero-
logical cross-reactivity between members of ﬂaviviruses. To date,
the presence of tick-borne ﬂaviviruses has not been conﬁrmed in
this region. The envelope domain III (EDIII) protein of ﬂaviviruses
has been described as highly antigenic, with type-speciﬁc epitopes
that may facilitate differentiation between ﬂaviviruses.
Methods & Materials: Serological assays using native and
recombinant antigens that can be handled in a biosafety level 2
or lower facility, were developed and evaluated for the detection
and differentiation of tick- and mosquito-borne ﬂaviviruses in the
Free State province. A total of 2393 serum samples from a variety of
species including humans, cattle and sheep were tested using Kun-
jin virus (KUNV) cell lysate antigen for detection of anti-ﬂavivirus
antibodies in an indirect IgG enzyme-linked immonosorbent assay
(ELISA). To further differentiate positive reactors on KUNV assay
for antibodies against tick- or mosquito-borne ﬂaviviruses, recom-
binant EDIII (r-EDIII) proteins of Langat virus (LGTV), WNV and
WESSV were expressed in a bacterial expression system and used
in ELISA.
Results: A total of 722 samples were positive on KUNV anti-
gen, of which 71, 457 and 431 were positive on the r-LGTVEDIII,
r-WNVEDIII and r-WESSVEDIII, respectively. A total of 70 sam-
ples were reactive against KUNV antigen but did not react with
recombinant antigens, suggesting thepresenceof otherﬂaviviruses
circulating in the Free State province for which speciﬁc r-EDIII
assays were not available.
Conclusion: The EDIII protein is a useful tool in the detection
and differentiation of ﬂaviviruses in resource-limited laboratories.
The prevalence of WESSV was shown to be similar to that of WNV
with high co-circulation rates in similar locations. The presence of
tick-borne ﬂaviviruses is also suggested. Results will be conﬁrmed
further by virus neutralization assays.
http://dx.doi.org/10.1016/j.ijid.2014.03.1361
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Background: The aim of this study was to evaluate the long-
termefﬁciency of lamivudine (LAM) treatment over a 5-year period
and toexplorehowmanypatientsdroppedout fromthe lamivudine
treatment because of developed reisistance.
Methods & Materials: We analyzed retrospectivly to whom we
began LAM because of chronic hepatitis B proven by liver biopsy,
from 2005 to 2013. A total 77 (48 male, 29 female) patients were
included in this study in Kocaeli. The 19 patients showed virologi-
cal breakthrough after a 15-monthmedian treatment (range 1-78).
RT region analysis was performed in 19/77 breakthrough patients
and LAM resistant mutations were found in 19. No signiﬁcant side
effects were observed. We analyzed the HBV polymerase gene by
ampliﬁcation and direct sequencing procedures. After conﬁrming
LAM resistance in 19 patients, we changed the treatment from LAM
to other oral antivirals (8 tenofovir, 7 adefovir, 4 entecavir). From
this 7 patients who became adefovir 4 patients did not response
to adefovir at 1.year of treatment. In 2 patients we found resis-
tance to adefovir. The most common LAM resistance mutations
were rtM204I/V, rtL180M and rtT184A/I/S, respectively, while
rtA181T/V and rtN236T substitutions were the most frequently
observed ADV resistance mutations. From 1 tenofovir patient we
did not become response, but there is no resistance. It could be due
to patients noncompliance.
Results: In long-term responder patients, continuation of LAM
monotherapy resulted in persistent viral suppression inmost cases
75.32% with undetectable HBV DNA by real-time PCR. But there is
no patients, cleared HBsAg.
Conclusion: Selection of LAM resistance was 24.67%, however,
can still occur evenafter successful long-termtherapy, thus empha-
sising the importance of a careful virological monitoring, because
in any time it could be develop resistance to LAM.
http://dx.doi.org/10.1016/j.ijid.2014.03.1362
